Compare SELX & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SELX | NOTV |
|---|---|---|
| Founded | 2021 | 1974 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.8M |
| IPO Year | 2023 | 1997 |
| Metric | SELX | NOTV |
|---|---|---|
| Price | $0.35 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 4.8M | 2.3M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.20 | $0.08 |
| 52 Week High | $1.48 | $3.19 |
| Indicator | SELX | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 40.75 |
| Support Level | $0.34 | N/A |
| Resistance Level | $0.46 | $0.34 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 36.18 | 41.68 |
Semilux International Ltd is a company that operates through its subsidiaries which is an optical and 3D sensing technology company that is involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR).
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.